These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36644226)

  • 1. Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.
    Kapadia SN; Eckhardt BJ; Leff JA; Fong C; Mateu-Gelabert P; Marks KM; Aponte-Melendez Y; Schackman BR
    Drug Alcohol Depend Rep; 2022 Dec; 5():. PubMed ID: 36644226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination.
    Behrends CN; Eggman AA; Gutkind S; Bresnahan MP; Fluegge K; Laraque F; Litwin AH; Meissner P; Shukla SJ; Perumalswami PV; Weiss J; Wyatt BE; Schackman BR
    J Public Health Manag Pract; 2019; 25(3):253-261. PubMed ID: 29975342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation and first-year operating costs of an academic medical center-based syringe services program.
    Bartholomew TS; Patel H; McCollister K; Feaster DJ; Tookes HE
    Harm Reduct J; 2021 Nov; 18(1):116. PubMed ID: 34798887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of opioid overdose education and naloxone distribution in New York City.
    Behrends CN; Gutkind S; Winkelstein E; Wright M; Dolatshahi J; Welch A; Paone D; Kunins HV; Schackman BR
    Subst Abus; 2022; 43(1):692-698. PubMed ID: 34666633
    [No Abstract]   [Full Text] [Related]  

  • 5. What Is the Financial Impact of Orthopaedic Sequelae of Intravenous Drug Use on Urban Tertiary-care Centers?
    Dwivedi N; Breslin MA; McDermott A; Lin S; Vallier HA; Tornetta P
    Clin Orthop Relat Res; 2020 Oct; 478(10):2202-2212. PubMed ID: 32667752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing blood-borne virus infection in people who inject drugs in the UK: systematic review, stakeholder interviews, psychosocial intervention development and feasibility randomised controlled trial.
    Gilchrist G; Swan D; Shaw A; Keding A; Towers S; Craine N; Munro A; Hughes E; Parrott S; Mdege N; Strang J; Taylor A; Watson J
    Health Technol Assess; 2017 Nov; 21(72):1-312. PubMed ID: 29208190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 9. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives.
    Surratt HL; Yeager HJ; Adu A; González EA; Nelson EO; Walker T
    Front Psychiatry; 2022; 13():905314. PubMed ID: 35706473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs.
    Tookes HE; Oxner A; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; McCollister K; Rodriguez A; Kolber MA; Chueng TA; Zayas S; McCoy B; Sutherland K; Archer C; Bartholomew TS
    Trials; 2023 Feb; 24(1):96. PubMed ID: 36750867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.
    Gutkind S; Starbird LE; Murphy SM; Teixeira PA; Gooden LK; Matheson T; Feaster DJ; Jain MK; Masson CL; Perlman DC; Del Rio C; Metsch LR; Schackman BR
    Drug Alcohol Depend; 2022 Mar; 232():109265. PubMed ID: 35042101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial.
    Eckhardt B; Mateu-Gelabert P; Aponte-Melendez Y; Fong C; Kapadia S; Smith M; Edlin BR; Marks KM
    JAMA Intern Med; 2022 May; 182(5):494-502. PubMed ID: 35285851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial.
    Hochstatter KR; Hull SJ; Sethi AK; Burns ME; Mundt MP; Westergaard RP
    J Med Internet Res; 2020 Sep; 22(9):e19703. PubMed ID: 32990630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City.
    Kapadia SN; Aponte-Melendez Y; Rodriguez A; Pai M; Eckhardt BJ; Marks KM; Fong C; Mateu-Gelabert P
    Harm Reduct J; 2023 Jul; 20(1):95. PubMed ID: 37501180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to HIV, Viral Hepatitis, and Substance Use Disorder Treatment/Overdose Prevention Services: A Qualitative Analysis of Syringe Service Programs (SSPs) Serving Rural PWID.
    Carnes NA; Asher AK; Bohm MK; Bessler PA
    Subst Use Misuse; 2021; 56(13):1933-1940. PubMed ID: 34353216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.